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Lower respiratory tract infections is one of the leading causes of death in children under 5 
years of age. In the advent of HIV, much of these lower respiratory tract infections are 
attributed to opportunistic infections such as Pneumocystis jiroveci pneumonia (PJP) and 
Cytomegalovirus (CMV). Short of a lung biopsy, diagnosing CMV pneumonia has proven 
difficult. Some studies suggest that blood CMV viral load might be of benefit in making the 
diagnosis of CMV-associated pneumonia. There is currently a scarcity of literature with 
regards to classifying severity of CMV-associated pneumonia and whether the CMV viral load 
can be used as a predictive indicator of severity and outcome of CMV-associated pneumonia.  
 
Objectives  
To determine whether CMV viral load is a positive predictor of severity and outcome of CMV-
associated hypoxic pneumonia.  
 
Methods 
This was a retrospective descriptive study done in the Paediatric Intensive Care Unit (PICU) 
in Tygerberg Children’s Hospital, Western Cape, South Africa. Study participants were 
identified from the National Health Laboratory Service (NHLS) database as those patients in 
PICU less than 1 year of age with a positive cytomegalovirus viral load between 1 January 
2014 to 31 December 2015. Patient clinical, radiological, and biochemical data was collected 
and analyzed. 
Results 
A total of 87 patients were included in the study. Twenty-seven of these patients were HIV-
positive, 3 of which were on antiretroviral therapy. Comparisons were made between two 
groups (CMV VL ≤ 4 and > 4) based on the median blood CMV viral load in our study of 4.0 
(IQR 3.3-4.79). There was no difference in severity of disease based on Pa02/Fi02 ratio and x-
ray findings between the two groups. The mortality in the two groups was similar with a 90% 
survival rate. (p=0.37). Patients with higher CMV VL required a longer duration of high 
frequency oscillation ventilation (HFOV) (p=0.005), yet the mean length of PICU stay between 
the two groups was not statistically different. (p=0.43). Patients who had CMV viral load > 4, 
had an increased incidence of PJP co-infection (p=0.018), lower CD4 counts (p=0.0001) and 
higher HIV viral loads (p=0.049). All the patients with PJP-CMV co-infection were successfully 
treated and discharged. 
 




CMV viral load alone cannot diagnose pneumonia and showed limited utility in predicting the 
course and outcome of CMV-associated pneumonia in young infants. The association 
between CMV VL, PJP co-infection, lower blood CD4 count and HIV viral load suggests that 
CMV-associated pneumonia occurs in more immune suppressed young infants but the lack of 
disease severity being associated with the CMV VL limits the usefulness of the test in 
diagnosing CMV-associated pneumonia and the need for antiviral therapy. 
 
  






Lae lugweginfeksies is een van die hoofoorsake van dood in kinders onder 5 jaar. Met die 
aanslae van MIV, kan baie van hierdie infeksies toegeskryf word aan opportunistiese 
infeksies, soos Pneumocystis Jirovecii Longontsteking (PJL) en sitomegalovirus (SMV). 
Buiten‘n longbiopsie, is dit moeilik om SMV-longontsteking te diagnoseer. Sommige studies 
stel voor dat bloed met ‘n SMV viruslade mag bydrae tot ‘n suksesvolle diagnose van SMV-
geassosieerde longontsteking. Huidiglik is daar‘n tekort aan navorsing aangaande die 
klassifisering van SMV-geassosieerde longonsteking se ernstigheid, sowel as antwoorde 
rondom maniere hoe die SMV viruslade mag bydrae tot ‘n voorspelling van ernstigheidsgraad 
en uitkoms van SMV-geassosieerde longonsteking.  
 
Mikpunte 
Om vas te stel of SMV-viruslade ‘n positiewe voorspeller is vir die graad van ernstigheid en 
uikoms van SMV-geassosieerde longontsteking.  
 
Metodes 
Hierdie was ‘n retrospektiewe beskrywende studie, afgelê in die Pedriatiese Intensiewe 
Sorgeenheid (PISE) by Tygerberg Kinderhospitaal in die Wes Kaap, Suid Afrika. Deelname 
aan die studie was vasgestel deur pasiënte te identifiseer (op die Nasionale 
Gesondheidslabrotorium Diens databasis) wat in die PISE opgeneem is, minder as een jaar 
oud is, en gediagnoseer is met ‘n positiewe SMV-viruslade tussen 1 Januarie 2014 en 31 
Desember 2015. Kliniese, radiologiese, en biochemiese data is ingesamel en analiseer.  
 
Uitslae 
87 Pasiënte is in die studie ingesluit. Van hierdie, is 27 getoets as MIV-positief, waarvan 3 op 
antiretrovirale-terapie was. Twee groepe was onderskei (SMV VL ≤ 4 en > 4) gebaseer op die 
mediaan bloed SMV-virale lade in ons studie van 4.0 (IQR 3.3-4.79). Daar was geen verskil 
in ernstigheid van die siekte gebaseer op Pa02/Fi02 verhouding en X-strale nie. Die 
sterftekoers in die twee groepe was soortgelyk, met ‘n 90% oorlewingssyfer. (p=0.37). 
Pasiënte met ‘n hoër SMV VL het langer behandelings van hoëfrekewensie ventilasie (HFV) 
benodig (p=0.005), tog het die gemiddelde lengte van PISE-opname tussen die twee groepe 
nie statisties verskil nie (p=0.43). Pasiënte met ‘n SMV VL van > 4 het ‘n groter kans gestaan 
van ‘n PJP mede-infeksie (p=0.018), laer CD4-tellings (p=0.0001), en hoër MIV-tellings 
(p=0.049). Al die pasiënte met PJP-SMV infeksie was suksesvol behandel en ontslaan.  
Gevolgtrekking 
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SMV-VL alleen kan nie longontsteking diagnoseer nie. Dít dui op ‘n beperkte bruikbaarheid in 
die voorspelling van die verloop en uitkoms van SMV-geassosieerde longontsteking in jong 
kinders. Die assosiëring tussen SMV VL, PJP mede-infeksie, laer bloed CD4 telling, en MIV 
VL stel voor dat SMV-geassosieerde longontsteking meer gereeld voorkom in jong kinders 
met verswygde-immuunstelsels. Die tekort aan siekte-ernstigheid assosiasie met die SMV VL 
beperk egter die bruikbaarheid van die toets in die diagnose van SMV-geassosieerde 
longontsteking en die noodsaaklikheid vir ‘n antivirale terapie.  
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Chapter 1: Introduction 
 
In 2014 there were 2.6 million children globally living with HIV. Eighty-eight percent of these 
children were from Sub-Saharan Africa. [1] Lower respiratory tract infections are a common 
complication of HIV. [2] In 2015, the leading cause of death for children under 5 years of age in 
the post neonatal period was lower respiratory tract infections at 13%. [3] 
 
Pneumocystis jiroveci pneumonia is usually the first manifestation of HIV disease in children 
under the age of 6 months.[4,5,6] Pneumocystis jiroveci pneumonia, also known as PJP, is an 
important AIDS defining infection and has a high mortality rate.[6,7,8] It is responsible for as 
many as one third to one half of all HIV-related deaths in African infants.[9] HIV co-infection 
negatively influences the course of pneumonia, especially in hospital settings owing to longer 
stays and higher mortality rates, as shown by one study.[8] Outcomes for PJP in children are 
generally poor.[4] Some authors have suggested that the outcomes are even worse when 
associated with CMV coinfection, whereas others have found no significant difference in 
outcomes in CMV/PJP co-infected children[4,10]  
 
Human cytomegalovirus, also known as Human Herpesvirus 5, is an ubiquitous-
herpesvirus.[11] The prevalence of cytomegalovirus infection is high in patients infected with 
HIV.[12,13] It can present in various forms ranging from asymptomatic virus shedding to retinitis, 
central nervous system or pulmonary involvement and gastrointestinal or wasting 
syndromes.[12] In one South African study it was found that CMV-associated pneumonia was 
three times more common in HIV-infected children than uninfected children.[14] It has been 
shown that prevalence of CMV infection peaks first at 6 months of age, presumably denoting 
congenital infection, and peaks again between 13 and 24 months, indicating acquired 
infection.[15]  In younger children primary CMV infection causes pneumonitis, hepatomegaly 
and petechial rashes, whereas in older children and adolescence CMV may cause syndrome 
of fatigue, malaise, myalgia, headache, fever, hepatosplenomegaly, elevated liver enzymes 
and atypical lymphocytosis. Despite signs and symptoms of CMV infection being diverse ‒ 
most cases are still subclinical. [16] Symptoms of CMV associated pneumonia include coughing, 
shortness of breath, fever and weight loss. Signs include adventitious sounds on auscultation, 
hypoxaemia and requirement of ventilatory support.[17] As with most viral pneumonias x-ray 
findings are nonspecific and may include: unilateral or bilateral streaky densities, confluent 
mottled opacities, a diffusely granular appearance with air-bronchograms or show alveolar air-
displacement.[17,18] There is also an overlap of findings on x-ray between those with CMV 
pneumonia and PJP making the diagnosis difficult.[19]  Plain film radiographic findings of CMV 
infection may be very subtle and easily missed, thus computed tomography is a more reliable 
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modality, especially in immunocompromised patients.[17] CT findings include diffuse ground-
glass opacities and consolidations, atelectasis, air-trapping, and rarely reticular and nodular 
patterns.[17]  
Definitive diagnosis of CMV pneumonia requires histologic confirmation on lung biopsy. [12] In 
our setting, routine lung biopsy in all children admitted with hypoxic pneumonia does not only 
carry risk but it is also unfeasible.  Without lung biopsy, accurate diagnosis of CMV pneumonia 
is difficult. Therefore, less invasive investigations are preferred. Monitoring of CMV viraemia 
by qualitative and quantitative polymerase chain reaction (PCR) is widely used in solid organ 
and bone marrow transplant recipients for the diagnosis and treatment of CMV infection and 
disease. Signs and symptoms of pulmonary disease coupled with detection of CMV in BAL 
fluid or lung tissue is considered internationally accepted criteria for diagnosing CMV in 
transplant patients.[20] This criteria, however, is not useful in the setting of HIV infection as BAL 
fluid is reported to lack utility in diagnosing CMV associated pneumonia in HIV-infected 
patients.[21] Quantifying CMV viral load in non-bronchoscopic bronchoalveolar lavage 
specimens is useful in diagnosing CMV pneumonitis in infants and is more predictive than 
plasma viral load.[22] 
There is existing evidence that the degree of CMV dissemination in the blood, which is 
measured by CMV load values, is a significant risk factor for progression from CMV infection 
to symptomatic disease.[23] A Kenyan study on HIV-infected children reported a peak in serum 
CMV viral load values soon after primary CMV infection and in advanced HIV disease.[24] An 
autopsy-based study in HIV-infected adults reported that a cutoff of > 4.0 log copies/mL has 
a specificity and positive predictive value of 100%, respectively, in predicting CMV disease.[25] 
Hsiao et al. showed, in a cross-sectional study on children in the Western Cape, that 76% of 
their patients who had CMV pneumonia (based on a positive CMV PCR on NPA, IS or BAL) 
also had CMV viral load logs of ≥ 4.1 copies/ml. Interestingly, of those who had CMV 
pneumonia, 89% of them were HIV infected. [26] 
As quantitative CMV PCR is best used to rule in, rather than to rule out CMV disease in HIV-
infected individuals at high risk [21,25], it is possible that patients who did have CMV pneumonia 
were missed. Due to these limitations, lung biopsy still remains the gold standard in diagnosis 
in CMV pneumonia. There is currently no data comparing confirmed CMV pneumonia on lung 
biopsy and CMV viral load. It has been shown that CMV load is more useful in assessing the 
response to antiviral treatment and to determine antiviral treatment endpoints rather than 
severity of disease and outcome in patients after solid organ transplantation.[27] In a 
retrospective descriptive study done in a Western Cape PICU, prior to the implementation of 
Stellenbosch University  https://scholar.sun.ac.za
14 
 
treatment for CMV,  it was shown that CMV pneumonia was a contributor to the high mortality 
rate of the cohort and it’s has since been recommended that all immunocompromised infants 
being ventilated for severe pneumonia be treated empirically for CMV and PJP infection.[28] 
Some suggest that the primary role of ganciclovir is in the prevention of CMV infection, 
however, it is still a very effective treatment for CMV infection. [29] Valganciclovir is a safe and 
useful alternative oral therapy. [30] Foscarnet and cidofovir have been recommended for 
patients with ganciclovir-resistant virus. [31]  
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Chapter 2: Research Justification 
Research Question: Is CMV viral load a good predictor of CMV-associated pneumonia 
severity and outcome? 
There is currently a scarcity of literature with regards to classifying severity of CMV-associated 
pneumonia and whether the CMV viral load can be used as a predictive indicator of severity 
of disease and disease outcome.  
 
Null hypothesis: 
The null hypothesis of this study is that the CMV viral load does not influence the severity and 
outcome of CMV-associated hypoxic pneumonia. 
 
Primary Aim: To determine whether CMV viral load is a positive predictor of severity and 
outcome of CMV-associated hypoxic pneumonia.  
Severity of disease is determined by three factors: 
1. Pa02/Fi02 ratio on admission and 24 hours after admission. A Pa02/Fi02 ratio of ≤ 200 
(suggestive of acute respiratory distress syndrome) is indicative of severe lung 
disease.  
2. Chest x-ray findings. Diffuse alveolar pattern changes is suggestive of severe lung 
disease. 
3. Length of invasive ventilation required. This includes HFOV and IPPV.  
 
Factors differentiating outcome would include: 
1. PICU mortality 
2. Morbidity: Supplementary oxygen dependency 28 days after admission 
 
Secondary Aim: 
1. To identify the risk factors influencing outcome of CMV-associated pneumonia. 
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Chapter 3: Material and Methods 
 
Setting 
This was a retrospective descriptive study done in the Paediatric Intensive Care Unit (PICU) 
in Tygerberg Children’s Hospital, Western Cape, South Africa. The PICU, a ten-bed unit, 
serving a population of approximately 2 million persons and admits children aged 2 weeks to 
13 years of age. The Tygerberg Children’s Hospital is situated in the G Block of the Tygerberg 
Hospital and is part of the larger Tygerberg Hospital, which is the academic training hospital 
of the University of Stellenbosch. This hospital serves the immediate surrounding areas, 
providing primary and secondary health care to children, as well as tertiary care to all 
paediatric patients in Metro East, and the Northern and Eastern rural districts of the Western 
Cape.  
Population 
Study participants were identified from the National Health Laboratory Service (NHLS) 
database as those patients in Tygerberg PICU (Ward A9) who were less than 1 year of age 
and had a positive cytomegalovirus viral load between 1 January 2014 to 31 December 2015 
and had been admitted to the PICU with hypoxic pneumonia. No formal sample size was 
calculated since all objectives are descriptive in nature. The sample size was determined by 
the number of infants admitted to the PICU with hypoxic pneumonia, the number of infants 
with hypoxic pneumonia who had a blood CMV viral load performed, logistical constraints and 
availability of eligible files within the sampling period. 
 
Inclusion criteria 
● Patients less than 1 year of age admitted to paediatric intensive care unit with hypoxic 
pneumonia. 
● Admission period from 1 January 2014 to 31 December 2015. 
● Patients with a positive CMV viral load. 
 
Exclusion criteria 
● Incomplete or missing information 
● CMV viral load not done or lower than detectable levels 
● Acute respiratory distress syndrome not related to lung disease 
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Outline of procedure 
 
Study participants were identified from the National Health Laboratory Service database as 
those patients in Tygerberg PICU (Ward A9) who were less than 1 year of age and had a 
positive cytomegalovirus viral load between 1 January 2014 to 31 December 2015. A formal 
request was sent to the NHLS to extract this information. 
 
Retrieval of folders and data abstraction were done by the principal investigator.  Patient clinical 
data was collected retrospectively from their patient files: either from the hard copy patient files or 
from the electronic patient files on the Enterprise Content Management (ECM) system. 
Radiological data was collected from the Tygerberg iSite Enterprise System and interpreted by 
the study supervisors. All other blood results were collected from the National Health Laboratory 
Service data base. 
 
Each patient enrolled in the study was assigned a unique patient identifier number and a paper 
based case report form was used to collect the data from the laboratory and radiology databases 
and clinical records. The nutritional status was determined by the standard deviation classification 
for weight for age by the World Health Organisation. This data was then entered into an electronic 
database. Patient names, hospital numbers and physical addresses were not entered in the 
electronic database.  
 
Variables collected: Age, sex, HIV status etc. (see Appendix A) 
 
Definitions: 
● Hypoxic pneumonia: a pneumonic process requiring oxygen support (eg. Nasal 
prongs, continuous positive airway pressure, intermittent positive pressure, high 
frequency oscillation ventilation) 
● PIM2 score: scoring system for rating the severity of medical illness for children, 
one of several ICU scoring systems. 
 
All data was handled and managed according to Good Clinical Practice (GCP) requirements 
and ethical standards. The database (checked for accuracy and completeness) were stored 
on a laptop computer, which was kept in a locked cabinet in a locked office. Copies were used 
to perform calculations and analysis. The database was backed up on a daily, weekly, monthly 
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and 6 monthly basis onto a storage disk. The paper based case report forms were stored 
separately. All paper documents were kept in a locked cupboard.  
 
Statistical Analysis 
Data analyses were performed using the STATISTICA data analysis software system. 
Numerical data was presented as means and standard deviations. Categorical data presented 
as numbers and proportions. T-tests were used to compare numerical data. Comparison of 
proportions was used to compare categorical data. ANOVA (Analysis Of Variance) was used 
for the determination of difference between groups. AUC (area under the curve) was used to 
predict the cut-off levels for variables of interest.  Significance was set at p < 0.05. 
 
Ethics 
The research Protocol “The role of cytomegalovirus in children with hypoxic pneumonia 
admitted to a paediatric intensive care unit” (S16/03/046) was approved by the Human 
Research and Ethics Counsel (HREC) of Stellenbosch University. 
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Chapter 4: Results 
 
Figure 1. Patient recruitment diagram 
A total of 559 CMV viral load samples from 1 January 2014 till 31 December 2015 were 
reviewed for inclusion in the study. One hundred and seventy-one of these samples were 
lower than detectable limits, 116 were repeat samples from the same patient during the index 
admission, 25 samples were from patients over the age of 1 year, 125 were samples taken 
from patients who were admitted in the NICU, 18 had been admitted to the PICU for other 
indications (post-operative care etc.) and not hypoxic pneumonia, 17 were excluded due to 
missing or incomplete information (files, arterial blood gas result sheets etc.). Eighty-seven 
patients met study definition and were included in the study. (Figure 1) 
The mean age for the group was 3.9 months (IQR:2.2-4.8). Forty percent (n=35) were born 
premature at birth. The nutritional status of the group showed that 43% (n=37) were classified 
as being severely underweight for age, 41% (n=36) were underweight for age and 16% (n=14) 
were of normal weight for age. The mean and standard deviation for weight for age Z-score 
was -2.68 (IQR: -3.0 - -0.83). Thirty-one percent (n=27) of the patients were HIV positive, of 
which 89% (n=24) were newly diagnosed with HIV at the index admission and not receiving 
antiretroviral therapy. Risk of mortality was assessed using the PIM 2 scores. The study group 
showed a mean risk of mortality of 24% (CI:18 to 29%). 
 
 




Table 1: Characteristics of children in study based on HIV status 
 
 
Graph 1: Statistical analysis of CMV VL on admission 
As per the statistical analyses of CMV viral loads done on admission (see Graph 1), the mean 
CMV viral load was 4.1 (SD 1.08) and the median was 4.0 (IQR 3.3-4.79). The authors decided 
make comparisons between two groups, where the CMV viral load log value was either ≤ 4.0 
or > 4.0. Coincidently, there is literature differentiating between these exact groups where a 
CMV viral load log ≤ 4.0 and >4.0 are classified as CMV infection and CMV disease 
respectively.  
 




Table 2: Comparison of patient characteristics according to CMV VL 
 
With regard to nutritional status, there were no significant differences between the two groups. 
Of the 27 patients who were HIV positive, 13 had CMV viral load log values ≤ 4 and 14 had 
CMV viral loads > 4.0 (p 0.38).  
 
Outcome was based on PICU mortality (either discharged or died) and morbidity (still requiring 
oxygen support 28 days from admission to PICU. Outcomes were favourable as 90% (n=78) 
of the patients were discharged from PICU, while 10% (n=9) died while in PICU. There was 
no significant differences between the two groups regarding mortality. Similarly, there were no 
differences between the 12 patients who were still on oxygen on day 28 after admission, 7 
were from the group with higher CMV viral loads (p=0.25).  Length of PICU stay did not differ 
between the two groups (p=0.43). (Table 2) 
 
 
Table 3: Comparison of blood results and oxygen requirement according to CMV VL 
 
 
As per Table 3, a comparison of CD4 counts and CMV VL showed that the mean absolute 
CD4 count in the group with higher CMV viral loads was significantly lower than in the group 
with lower viral loads.  (p 0.0001). The converse was true for HIV VL (p 0.049). Patients with 
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higher CMV viral loads had lower mean LDH levels when compared to the group with lower 
CMV viral loads (p 0.014). 
 
The only significant difference between those with higher and lower CMV viral loads with 
regards to duration of specific mode oxygen support needed showed that the group with higher 
CMV viral loads required a longer duration of HFOV (p 0.005).  
 
              Graph 2 and 3: ROC curves comparing PF ratio at admission and 24hrs, respectively, to CMV VL 
 
Receiver operating characteristic curves comparing Pa02/Fi02 ratios on admission and 24 
hours after to the blood CMV viral load log showed that on admission, the group with CMV 
viral load ≤ 4.0 was significantly different from the group with viral load > 4.0 when related to 
the Pa02/Fi02 ratio with a sensitivity of 0.64 (p 0.01), however, at 24 hours after admission the 
sensitivity is 0.55 (p 0.23). 
 
 
Table 4: Comparison between chest x-ray changes according to CMV VL 
NS=Not significant (sample size was too small to analyze) 
 
There were no significant differences with regard to x-ray findings between the two groups. 
While 21 (58%) of the 36 patients who had a diffuse alveolar pattern on x-ray indicating severe 
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disease were from the group with higher viral loads, however, the difference between those 
from the group with lower viral loads was not significant (p 0.08). 
 
 
Table 5: Other organisms grown on Tracheal Aspirate (in order of frequency) 
NS = not significant (sample size was too small to analyze), CMV VL = Cytomegalovirus viral load, RSV = Respiratory Syncytial 
VIrus, PJP = Pneumocystis jiroveci pneumonia, MRSA = Methicillin-resistant Staphylococcus aureus 
 
Multiple organisms were cultured from tracheal aspirate on admission (see Table 5), in order 
of highest to lowest frequency. A significant finding was that those with higher CMV viral loads 
also had a higher incidence of PJP co-infection (p 0.008). Rhinovirus (n=22) and RSV (n=17) 
were two most frequently observed organisms, however there was no significance difference 
in relation to CMV viral load (p=0.28 and p=0.22 respectively). All those with PJP co-infection 
were treated for CMV and subsequently discharged from PICU.  
 
 
Table 6: Patients who were not treated for CMV 
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In the study group 28 (32%) were not treated treatment for CMV-associated pneumonia. Two 
of these patients were HIV positive, 1 from each comparative group, and no patients in either 
groups had PJP co-infection. A total of 4 patients of this subset died during PICU admission, 
with only 1 of the deaths being from the group with the higher CMV viral loads. The patient 
that died was HIV infected.  No patients that were not treated for CMV-associated pneumonia 
required supplementary oxygen for greater than 28 days after admission. As the subset was 
so small, it was not statistically analyzed and is used for descriptive purposes. (Table 6) 
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Chapter 5: Discussion 
 
The main finding of this retrospective review was that in patients with CMV-associated 
pneumonia, there was no obvious association between CMV viral load and the course and 
outcome from CMV-associated pneumonia. Patients with higher CMV viral loads required a 
longer duration of HFOV, however there was no difference in length of PICU stay or mortality. 
There was a relation to CMV viral load and PJP co-infection with more PJP co-infection 
occurring in patients with higher CMV VL. There was a 100% survival among those treated for 
CMV-PJP co-infection in this study.  
 
While CMV viral load in the group with log values ≤ 4 was a positive predictor of a Pa02/Fi02 
ratio on admission, the sensitivity was only 64% and at 24 hours after admission, it lacked 
utility as the sensitivity was only 55%. This illustrates that viral load was a poor predictor of 
disease severity in this study. This was not dissimilar to a prospective study by Cloete et al., 
[32] from the PICU at Steve Biko Academic Hospital, Pretoria, RSA, which reported that of the 
patients with hypoxic acute lower respiratory tract infection with a Pa02/Fi02 ratio of <200, only 
27% had CMV viral load log values > 4.0.   
 
Ranieri et al. [33] described diffuse alveolar disease as a pathological hallmark of ARDS.  Thirty-
six (41.4%) of the study population had a diffuse alveolar disease pattern on chest x-ray while 
only 21(58%) were from the group with CMV viral load log values of > 4.0, which according to 
literature is classified as CMV disease. In a 9-year retrospective study by Gie, et al. [34] that the 
most common causative organism diagnosed in open lung biopsy on patients that had diffuse 
lung disease, was CMV.  As there was no statistical significance difference between the two 
groups (viz. CMV VL ≤ 4 and CMV > 4) with regards to x-ray changes, and in particular, diffuse 
alveolar disease, we cannot confidently deduce that a CMV viral load > 4 equates to CMV-
associated pneumonia or that it predicts the severity of disease.   
 
The duration of HFOV needed, significantly differed between those with higher vs lower CMV 
viral loads, in that those with higher CMV VL needed a longer duration of HFOV, yet there was 
no difference in other ventilation modalities. Despite this fact, the length of PICU stay between 
the two groups showed no difference. There is a paucity of literature in our setting 
demonstrating the effect of the CMV viral load on length of ventilation, however, in Vietnam, 
Mai Doan et al. [35], showed that patients with CMV viral loads > 4 had a longer duration of 
oxygen support, however, the modalities of oxygen support were not stipulated. An audit of 
primary medical conditions in children admitted to the paediatric intensive care unit of 
Charlotte Maxeke Johannesburg Academic Hospital by Mopeli et al. [35] showed that children 
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who tested HIV PCR-positive had a significantly longer duration of ventilation than those who 
were exposed but uninfected but HIV exposed children were ventilated for 4 more days than 
those who were unexposed. As the HIV status in the Vietnamese study was not looked at, we 
cannot exclude how many of those that had longer oxygen requirements were HIV positive. 
We cannot, with confidence, say that there isn't a relationship between CMV viral load and 
duration of oxygen requirement as this could differ with HIV status.  Another shortfall was that 
of the HIV negative children in our group, we were unable to quantify how many of them were 
HIV exposed. In addition, many of the patients in our study had multiple organisms on tracheal 
aspirate which may have influenced the mode of ventilation required. 
 
There was a 90% PICU survival of the patients admitted to PICU with CMV-associated 
pneumonia with no difference in the two CMV viral load groups. It has been well documented 
by many authors in similar settings to our study that there is no significant difference in 
mortality between HIV infected and HIV uninfected children with pneumonia in PICU. [32,36,37] 
Our findings are consistent with those of Cloete et al. [32] where a multivariate analysis of the 
variables, including CMV viral load, that influenced mortality there was no single factor that 
influenced mortality. The survival in our study was akin to that of the study by Jeena and 
Githinji [37], who attributed better outcomes to treatment as opposed to studies done in the pre-
cART and pre-ganciclovir era in 2004/5, where the mortality rate of CMV-associated 
pneumonia in HIV positive children was 72% at Tygerberg Hospital [28] and 55% at Red Cross 
War Memorial Children's Hospital [14]. It is worth mentioning that of the 27 HIV-infected children 
in our population group, 89% (n=24) were newly diagnosed with HIV at the index admission 
and had not been commenced on cART.  
 
The PICU mortality for this study was 10.3% which was more than two times lower than the 
expected PIM2 mortality rate of 24%. Solomon et al. [38], based on a retrospective audit at the 
RCWMCH, showed the PIM2 score to be an appropriate mortality risk assessment score in 
the context of a PICU in South Africa (SA). The author did acknowledge, however, that further 
studies from multiple PICUs in SA, were needed to evaluate the use of the PIM 2 in the SA 
context as it could differ between PICUs. Regrettably, no such study had been undertaken in 
Tygerberg Hospital to determine whether the PIM 2 score was a valid assessment tool of 
mortality risk in that PICU. We therefore cannot postulate that, based on the PIM2 score, better 
outcomes were due to PICU practices itself or a lack of utility of the PIM2 score in our setting. 
An association between CMV VL and PJP co-infection was noted where the incidence of PJP 
co-infection was significantly higher in the group with CMV VL > 4. This was also observed by 
Zampoli et al. [14] in a prospective study in Cape Town that showed that CMV-associated 
pneumonia with PJP co-infection has a poor outcome. [4,10,14,28] In contrast, there was a 100% 
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survival of the patients in this study with PJP co-infection, albeit small number of patients with 
CMV-PJP co-infection. All of the co-infected patients were treated for CMV-associated 
pneumonia with ganciclovir. A decrease in mortality from PJP was also observed by Cloete et 
al. [32] in their study. One can conjecture that as poor mortality in these patients were seen in 
the pre-ganciclovir and pre-cART periods, the decline in mortality may be attributed to the 
availability and early use of ganciclovir and antiretroviral therapy. This is, however, pure 
conjecture and as no single factor is responsible for better outcome, many therapeutic 
interventions may contribute to it as well.  
 
Of interest was of the 14 patients with PJP co-infection, 50% were HIV-uninfected. Only three 
of these patients were investigated for an underlying primary immune deficiency. One of the 
CMV-PJP co-infected patients who was HIV-uninfected had an open lung biopsy performed. 
This resulted in a final diagnosis of pulmonary interstitial glycogenosis. Five (71%) of those 
who were HIV-uninfected also happened to have been premature at birth. The association 
between prematurity and PJP in HIV-uninfected patients is well documented.  The relationship 
between CMV VL and lower CD4 counts is worthy of being explored further. In our study where 
CD4 counts were significantly lower in patients with higher CMV viral loads. Many authors 
have described this relationship between CMV infection and low CD4 counts, where it has 
been postulated that the incidence of CMV infection is greater in those with lower CD4 counts. 
Our findings were similar to that of a study in India by Kannangai et al. [40]  
 
An interesting finding in this study was the significant difference in mean serum LDH levels in 
the two comparative groups. While LDH was elevated in both groups, as would be expected 
based on literature, the mean LDH was significantly lower in the group with higher viral loads. 
There is a lack of literature demonstrating a relationship between serum LDH values and CMV 
viral loads in patients being treated for CMV-associated pneumonia. The higher serum LDH 
levels were not associated with CMV-PJP co-infection.  
 
  





The most important limitation of the study was that without lung biopsy it is difficult to diagnose 
CMV pneumonia and without it, actual proof of CMV-associated pneumonia is remains 
uncertain, as documented in previous studies. The measure of viral load does not equate to 
pulmonary disease and while the majority of our participants had multiple pathogens isolated 
from tracheal aspirates, we cannot exclude that these pathogens were not the causative agent 
of the hypoxic pneumonia.  The second limitation was that of those patients who were HIV-
uninfected, we were unable to document the number that HIV-exposed but uninfected. This 
maybe important as infants cared for by HIV-infected parents are most likely to be exposed to 
a different pathogen load. The literature also suggests that HIV-exposed uninfected infants 
might have some degree of yet unexplained immune deficiency making them more vulnerable 
to develop opportunistic infections. In addition, only a fraction of the patients with PJP co-
infection had been investigated for a primary immune deficiency which had contributed to them 
developing CMV-associated pneumonia.  As this was a retrospective study, there were many 
different management techniques employed which could influence our results.  
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Chapter 6: Conclusion 
 
CMV viral load alone cannot diagnose CMV-associated pneumonia and showed limited utility 
in predicting the course and outcome of CMV-associated pneumonia. The obvious relation 
between CMV VL, PJP co-infection and CD4 count may suggest that the viral load is indicative 
of some underlying ill-defined disease process. This remains unclear from our study. As lung 
biopsy is not always feasible in our setting, a diagnosis of CMV pneumonia may need to be 
made by looking at multiple factors simultaneously, which include radiological changes, 
clinical presentation and laboratory investigation. The difficulty arises in patients who are HIV-
uninfected as CMV is more difficult to diagnose. Despite the increase in HIV awareness and 
availability of PMTCT to exposed babies, the majority of the HIV-infected patients were newly 
diagnosed on admission to PICU. This may be suggestive of failed PMTCT, poor surveillance 
or a lack of insight into the disease etc. While there is an improvement in the total number of 
newly diagnosed people since antiretroviral therapy becoming more readily available, it seems 
as though those who are infected by vertical transmission account significantly in the group 
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Chapter 7: Recommendations 
 
1. All HIV positive and HIV exposed children admitted with hypoxic pneumonia should be 
treated empirically for CMV and PJP regardless of CMV viral load value.  
2. In patients where CMV pneumonia is suspected, CMV viral load on BAL may prove 
more accurate in making the diagnosis in correlation with clinical and radiological 
findings. This hypothesis needs further investigation. 
3. All HIV-uninfected children diagnosed with PJP infection should be adequately worked 
up for primary immune deficiencies unless there is a known reason for their 
immunosuppression. 
4. All HIV-exposed infants are to be adequately placed on PMTCT and mothers are to be 
thoroughly counseled regarding the risk factors involved in increased transmission. 
There needs to be even more awareness surrounding HIV and every effort to 
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Appendix A (Case report form) 
 
 
Study Number: _________ 
 
Race:  
Black White Coloured Indian 
 




Area of residence: __________________________________________ 
 
 
Date of birth: ___________________        Weight (on admission): __________kg 
 
 
Date of admission to PICU (DD/MM/YY):______/______/______ 
 























Positive Negative Unknown 
 
If positive, is patient on HAART: 
Y N Unknown 
 
 
CD4 Count (Absolute): ____________________ 
HIV VL Log: ______________ 
 
 
Acute Phase Reactants (admission):  CRP: ______________  PCT: ______________ 
 
 
Blood Culture on admission: ______________________________________________________ 
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CMV Viral Load (Log):  ________________ 
 
 

















If yes, drug used: 
Ganciclovir 
 
Duration: _____________ (days) 
Valganciclovir 
 





1. Death Date of death (DD/MM/YY): ______/______/______ 







If yes,  
In-hospital oxygen Domiciliary oxygen 
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